K Izuhara

Kyushu University, Hukuoka, Fukuoka, Japan

Are you K Izuhara?

Claim your profile

Publications (48)173.81 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Asthma is a complex clinical syndrome characterized by variable airflow obstruction (some of which can be permanent), airway hyperresponsiveness (AHR), and cellular inflammation. It is a heterogeneous disorder, exhibiting multiple phenotypes, reflected by the many clinical aspects of the disease (1-5). Recent advances in the identification of serum biomarkers for asthma are important in its diagnosis, including determination of the asthma phenotype or endotype. Woodruff et al. emphasized the utility of periostin as a biomarker of TH 2-induced airway inflammation (6). This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Allergy 02/2015; 70(6). DOI:10.1111/all.12599 · 6.03 Impact Factor
  • S. Ohta · K. Izuhara ·

    Japanese Journal of Clinical Chemistry 01/2015; 44(1):30-36.
  • Source
    Kenji Izuhara ·

    Allergology International 06/2014; 63(2):141-2. DOI:10.2332/allergolint.14-ED-0732 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In steroid-naive patients with asthma, several gene variants are associated with a short-term response to inhaled corticosteroid (ICS) treatment; this has mostly been observed in Caucasians. However, not many studies have been conducted for other ethnicities. Here, we aimed to determine the relationship between the annual decline in forced expiratory flow volume in one second (FEV1 ) and the variant of the glucocorticoid-induced transcript 1 gene (GLCCI1) in Japanese patients with asthma receiving long-term ICS treatment, taking into account the effect of high serum periostin levels, a known association factor of pulmonary function decline and a marker of refractory eosinophilic/Th2 inflammation. In this study, 224 patients with asthma receiving ICS treatment for at least 4 years were enrolled. The effects of single-nucleotide polymorphisms (SNPs) in GLCCI1, stress-induced phosphoprotein 1 (STIP1), and T gene on the decline in FEV1 of 30 ml/year or greater were determined. Besides the known contributing factors, that is, the most intensive treatment step, ex-smoking, and high serum periostin levels (≥95 ng/ml), the GG genotype of GLCCI1 rs37973, and not other SNPs, was independently associated with a decline in FEV1 of 30 ml/year or greater. When patients were stratified according to their serum periostin levels, the GG genotype of rs37973 was significantly associated with blood eosinophilia (≥250/μl) in the high serum periostin group. A GLCCI1 variant is a risk factor of pulmonary function decline in Japanese patients with asthma receiving long-term ICS treatment. Thus, GLCCI1 may be associated with response to ICS across ethnicities.
    Allergy 03/2014; 69(5). DOI:10.1111/all.12400 · 6.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Recent findings indicate that periostin, an extracellular matrix protein induced by T helper 2 cytokines, plays a critical role in the pathogenesis of atopic dermatitis (AD). Objectives To determine whether serum periostin level is associated with clinical phenotype in adult patients with AD. Methods An enzyme-linked immunosorbent assay was performed to determine serum periostin levels in 257 adult patients with AD, 66 patients with psoriasis vulgaris (PV) as a disease control and 25 healthy controls. Serum periostin levels were analysed together with clinical characteristics and laboratory parameters, including thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), blood eosinophil count and total IgE. Immunohistochemical analysis evaluated the expression of periostin in association with various clinical phenotypes of AD. The effect of treatment on serum periostin level was also assessed. Results Serum periostin was significantly higher in patients with AD than in patients with PV and healthy controls. Periostin level was found to be positively correlated with disease severity, TARC level, LDH level and eosinophil count, but not with IgE level. Higher serum periostin level was observed in patients with extrinsic AD compared with patients with intrinsic AD; the positive correlation of disease severity disappeared in patients with intrinsic AD. Robust expression of periostin was detected in the dermis of patients with AD with erythroderma, lichenification and, to a lesser extent, scaly erythema. Serial measurement of serum periostin revealed decreased levels of periostin after treatment for AD. Conclusions Periostin may play a critical role in disease severity and chronicity in the pathogenesis of AD.
    British Journal of Dermatology 03/2014; 171(2). DOI:10.1111/bjd.12943 · 4.28 Impact Factor
  • Source
    Kenji Matsumoto · Kenji Izuhara ·

    Allergology International 03/2014; 63(1):1-2. DOI:10.2332/allergolint.14-ED-0696 · 2.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atopic dermatitis (AD) is a chronic inflammatory skin disease. Here, we show that phospholipase C-β3 (PLC-β3)-deficient mice spontaneously develop AD-like skin lesions and more severe allergen-induced dermatitis than wild-type mice. Mast cells were required for both AD models and remarkably increased in the skin of Plcb3(-/-) mice because of the increased Stat5 and reduced SHP-1 activities. Mast cell-specific deletion of Stat5 gene ameliorated allergen-induced dermatitis, whereas that of Shp1 gene encoding Stat5-inactivating SHP-1 exacerbated it. PLC-β3 regulates the expression of periostin in fibroblasts and TSLP in keratinocytes, two proteins critically involved in AD pathogenesis. Furthermore, polymorphisms in PLCB3, SHP1, STAT5A, and STAT5B genes were associated with human AD. Mast cell expression of PLC-β3 was inversely correlated with that of phospho-STAT5, and increased mast cells with high levels of phospho-STAT5 were found in lesional skin of some AD patients. Therefore, STAT5 regulatory mechanisms in mast cells are important for AD pathogenesis.
    Cell Reports 01/2014; 6(2). DOI:10.1016/j.celrep.2013.12.029 · 8.36 Impact Factor

  • Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 05/2013; 110(5):387-8. DOI:10.1016/j.anai.2013.01.024 · 2.60 Impact Factor
  • Y Yamaguchi · J Ono · M Masuoka · S Ohta · K Izuhara · Z Ikezawa · M Aihara · K Takahashi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Background:  Periostin, a matricellular protein, serves as a regulator of wound healing and fibrosis. The role of periostin in the pathogenesis of systemic sclerosis (SSc) is unknown. Objective:  To determine periostin levels in association with severity of skin fibrosis in patients with SSc. Methods:  Expression of periostin was immunohistochemically examined in the skin obtained from SSc patients and healthy controls. Enzyme-linked immunosorbent assay was performed to evaluate serum periostin levels in association with clinical characteristics in 56 patients with SSc (diffuse cutaneous SSc (dSSc), n=16; and limited cutaneous SSc (lSSc), n=40) and 66 healthy controls. Results:  Periostin was strongly expressed in the affected dermis from SSc patients. Periostin was co-localized in α-SMA-positive myofibroblasts and PECAM-1-positive endothelial cells in SSc dermis. Serum levels of periostin in dSSc patients were markedly elevated compared to those in lSSc patients and control subjects. Patients with lSSc had increased periostin levels compared with healthy controls. In addition, significantly higher levels of periostin were observed in dSSc patients with disease duration ≤5 years compared with those with disease duration >5 years. Furthermore, the modified Rodnan total skin thickness score (MRSS) was positively correlated with periostin levels in SSc patients. Serial analysis revealed a correlation between periostin and MRSS; namely, MRSS decreased in line with decreased periostin levels in some dSSc patients as the disease progressed. Conclusion:  An elevated periostin level in SSc patients was associated with severity of skin sclerosis. Periostin may be a potential biomarker for progressive skin fibrosis in SSc.
    British Journal of Dermatology 10/2012; 168(4). DOI:10.1111/bjd.12117 · 4.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We investigated the localization of periostin in middle ear specimens from patients with eosinophilic otitis media (EOM) and from a newly constructed animal model for EOM. Periostin-positive immunostaining was observed in the middle ear sections obtained from the EOM patients. Immunoreactivity for periostin was also seen in the animal model. These results suggest that periostin plays an important role in subepithelial fibrosis in the middle ear in EOM. The purpose of the present study was to investigate the role of periostin in the middle ear of EOM patients and an animal model. Histological and immunohistochemical analyses for periostin were carried out in the middle ear specimens of six EOM patients with/without asthma. An animal model of EOM was constructed by intraperitoneal and topical sensitization with ovalbumin (OVA). Histological and immunocytochemical analyses for periostin were also performed in this model. Immunoreactivities for periostin were observed in the basement membrane and extracellular matrix of the middle ear sections obtained from all EOM patients with/without asthma. In the animal model, eosinophil infiltration and middle ear mucosa thickness were observed. Moreover, periostin-positive immunostaining was shown in the extracellular matrix of the middle ear mucosa on the side topically boosted by OVA.
    Acta oto-laryngologica 06/2012; 132(8):838-44. DOI:10.3109/00016489.2012.668708 · 1.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: May-Hegglin anomaly (MHA) is a rare autosomal dominant disease characterized by macrothrombocytopenia and leukocyte inclusions with microfilaments in the ribosomes. Mutations in the MYH9 gene, encoding non-muscle myosin heavy chain IIA (NMMHC-IIA) have been identified in patients with MHA and other MYH9-related diseases. Two young males (an older and younger brother) presented with macrothrombocytopenia and leukocyte inclusion bodies. Electron microscopy (EM) revealed parallel filaments in leukocyte inclusion bodies characteristic of MHA. Immunofluorescence microscopy (IF) showed NMMHC-IIA antibodies in 1 - 2 leukocyte inclusion bodies. These findings were consistent with MHA and they were identified to express the MYH9 mutation, D1424H. The older brother underwent a renal biopsy because of persistent proteinuria. Histology revealed mesangial proliferative glomerulonephritis with granular deposits of IgG and C1q. EM showed that the dense deposits were located in subendothelial cells, mesangial cells and Bowman's capsule. Immunocytochemistry revealed that NMMHC-IIA antibodies were localized in podocyte and endothelial cells in the glomerulus. Moreover, the expression of nephrin and podocin, slit diagram protein, was normal. An inflammatory mechanism may occur separately from MYH9-related disease. This report presents a case of MHA with immune complex-related nephropathy.
    Clinical nephrology 03/2011; 75(3):255-62. DOI:10.5414/CNP75255 · 1.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Idiopathic interstitial pneumonias (IIPs) are histopathologically classified into several types, including usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and cryptogenic organising pneumonia (COP). We investigated whether periostin, a matrix protein, could be used as a biomarker to assess histopathological types of IIPs. We performed immunohistochemical analyses in each histopathological type of IIP, examined serum levels of periostin in IIP patients and analysed the relationship between serum levels of periostin and the pulmonary functions in patients with idiopathic pulmonary fibrosis (IPF). Periostin was strongly expressed in lungs of UIP and fibrotic NSIP patients, whereas expression of periostin was weak in the lungs of cellular NSIP and COP patients, as well as in normal lungs. Serum levels of periostin in IPF were significantly higher than those of healthy subjects and COP patients. Furthermore, periostin levels in IPF patients were inversely correlated with their pulmonary functions. Thus, we have found that periostin is a novel component of fibrosis in IIP. Periostin may be a potential biomarker to distinguish IIP with fibrosis.
    European Respiratory Journal 12/2010; 37(5):1119-27. DOI:10.1183/09031936.00059810 · 7.64 Impact Factor
  • K Izuhara ·

    Cellular and Molecular Life Sciences CMLS 05/2009; 66(10). DOI:10.1007/s00018-009-9302-4 · 5.81 Impact Factor
  • K Izuhara · S Ohta · H Shiraishi · S Suzuki · K Taniguchi · S Toda · T Tanabe · M Yasuo · K Kubo · T Hoshino · H Aizawa ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Mucus production is a cardinal feature of bronchial asthma, contributing to morbidity and mortality in the disease. Goblet cells are major mucus-producing cells, and goblet cell hyperplasia (GCH) is one feature of airway remodeling, defined as structural changes occurring in the airway. A number of studies have demonstrated that Th2-type cells play critical roles in this process and that particularly interleukin-13 (IL-13), among Th2-type cytokines, is a central mediator for GCH. However, the mechanism underlying how Th2 cytokines induce mucus production or GCH is poorly understood. Mouse calcium-activated chloride channel-3 (mCLCA-3; gob-5)/human CLCA-1 acts as a downstream molecule of Th2 cytokines, IL-4/IL-9/IL-13 signals, playing an important role in mucus production. Moreover, we have recently found that pendrin, an anion transporter, is induced by IL-13 and causes mucus production in airway epithelial cells. It is hoped that if we can clarify how mucus is produced, this will lead to development of novel therapeutic reagents to suppress mucus production in bronchial asthma.
    Current Medicinal Chemistry 02/2009; 16(22):2867-75. DOI:10.2174/092986709788803196 · 3.85 Impact Factor
  • K Izuhara · S Ohta · S Kanaji · H Shiraishi · K Arima ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The inhibitory mechanism against proteases is important in the maintenance of homeostasis or health in the body. The human ovalbumin serpin (ov-serpin)/clade B serpin family is one group of the human serpins, a family of serine protease inhibitors. They have acquired diversity in the profiles of target proteases, inhibitory mechanisms, and localization patterns during their evolution. Most serpins target serine proteases, however, some ov-serpins target only cysteine proteases or both serine and cysteine proteases and furthermore, several ov-serpins do not possess inhibitory activities. Although the ov-serpins act primarily as intracellular serpins, some show extracellular and nuclear localizations. Such diversity enables the ov-serpins to play multiple physiological roles in the body. Recent analyses have revealed that the functions of human ov-serpins are more diversified than we previously knew. In this article, we describe recent progress in our understanding of how the human ov-serpin/clade B serpin family demonstrates diversity.
    Cellular and Molecular Life Sciences CMLS 07/2008; 65(16):2541-53. DOI:10.1007/s00018-008-8049-7 · 5.81 Impact Factor
  • Source
    K Izuhara · K Arima · S Kanaji · S Ohta · T Kanaji ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of allergic diseases has dramatically increased in recent decades, especially in urban and industrialized areas. It is important socially as well as medically to establish more useful strategies to overcome allergic disorders. Bronchial asthma is a complex disease characterized by airway inflammation involving a Th2-cytokine, interleukin (IL)-13. A substantial body of evidence has accumulated pointing to the pivotal role of IL-13 in the pathogenesis of bronchial asthma, based on mainly analyses of mouse models. In addition to such analyses, the high expression of IL-13 in lesions and genetic association of several genes coding IL-13 signaling molecules with bronchial asthma have raised the possibility that IL-13 plays a pivotal role in the onset or exacerbation of human bronchial asthma. Therefore, IL-13 and its signal pathway are thought to be promising targets to develop a therapeutic agent for bronchial asthma. In this article, we describe how IL-13 is involved in the pathogenesis of bronchial asthma and then how therapeutic agents to block IL-13 signals are developed for bronchial asthma.
    Current Medicinal Chemistry 02/2006; 13(19):2291-8. DOI:10.2174/092986706777935140 · 3.85 Impact Factor
  • K Mitsuishi · T Nakamura · Y Sakata · N Yuyama · K Arima · Y Sugita · H Suto · K Izuhara · H Ogawa ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Although it is thought that both Th1- and Th2-type inflammations are involved in the pathogenesis of atopic dermatitis (AD), it is controversial which immune response is more involved in regulating the clinical severity of AD. We recently found that the squamous cell carcinoma antigens 1 (SCCA1) and SCCA2 are novel biomarkers of bronchial asthma, downstream of IL-4 and IL-13. We examined whether SCCA1 and SCCA2 could also serve as biomarkers of AD, reflecting its Th2-type immune responses, and whether the expression level of SCCA was correlated with clinical severity of AD. We compared the expression of SCCA1 and SCCA2 at the mRNA and protein levels in both involved and uninvolved skin of AD patients and in normal control skin. We next analysed induction of SCCA by IL-4 or IL-13 in keratinocytes. Finally, we compared the serum level of SCCA with laboratory parameters reflecting Th2-type inflammation and clinical severity in AD patients. SCCA1 and SCCA2 were highly expressed in involved skin of AD patients, compared with their uninvolved skin, at both mRNA and protein levels. SCCA protein was dominantly expressed in suprabasal keratinocytes in the epidermis of AD patients. Either IL-4 or IL-13, but not IFN-gamma or TNF, induced production of SCCA in keratinocytes. These result suggest that SCCA is induced in AD skin, probably due to direct actions of IL-4 and/or IL-13 on keratinocytes. Serum levels of SCCA were well correlated with eosinophil numbers and serum lactate dehydrogenase levels, and weakly with serum IgE levels, in AD patients. Furthermore, serum levels of SCCA were strongly correlated with clinical severity. Th2-type inflammation dominantly regulates the clinical severity of AD, and SCCA is a relevant biomarker of AD, reflecting both Th2-type inflammation and clinical severity.
    Clinical & Experimental Allergy 11/2005; 35(10):1327-33. DOI:10.1111/j.1365-2222.2005.02353.x · 4.77 Impact Factor
  • K. Izuhara · K. Arima · K. Masumoto · S. Kanaji · T. Kanaji ·

    Medicinal Chemistry Reviews - Online 04/2005; 2(2):149-152. DOI:10.2174/1567203053586964
  • Y Sakata · K Arima · K Takeshita · T Takai · S Aoki · H Ogawa · H Sugihara · K Fujimoto · K Izuhara ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The squamous cell carcinoma antigen 1 (SCCA1) and SCCA2 are unique serpins that can inhibit cysteine proteinases. SQN-5, their mouse ortholog, has already been identified, and its inhibitory property has been characterized; however, its biological role has remained undefined. Furthermore, no other mouse homolog of SQN-5 has been known. We characterize three mouse members of SCCA-related molecules including SQN-5 in this article. Serpinb3a (SQN-5) and Serpinb3b, but not Serpinb3c, were functional, inhibiting both serine and cysteine proteinases with different inhibitory profiles due to the difference of two amino acids in their reactive site loops. Serpinb3a was ubiquitously expressed in most tissues, whereas expression of Serpinb3b was limited to keratinocytes. Keratinocytes secreted both SCCA-related proteins, Serpinb3a and Serpinb3b. These results indicate that Serpinb3a and Serpinb3b may play different roles by inhibiting intrinsic or extrinsic proteinases with different expression distributions and different inhibitory profiles.
    Biochemical and Biophysical Research Communications 12/2004; 324(4):1340-5. DOI:10.1016/j.bbrc.2004.09.204 · 2.30 Impact Factor
  • K. Izuhara · K. Arima · N. Yuyama · Y. Sakata · K. Masumoto ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Bronchial asthma is a complicated and diverse disorder affected by genetic and environmental factors. It is widely accepted that it is a Th2-type inflammation originating in lung and caused by inhalation of ubiquitous allergens. The complicated and diverse pathogenesis of this disease is yet to be clarified. Functional genomics is the analysis of whole gene expression profiling under given condition, and microarray technology is now the most powerful tool for functional genomics. Several attempts to clarify the pathogenesis of bronchial asthma have been carried out using microarray technology, providing us some novel pathogenic mechanisms of bronchial asthma as well as the information of gene expression profiling. In this article, we review the outcomes of these analyses by the microarray approach as applied to bronchial asthma.
    Current Pharmacogenomics 11/2004; 2(4):351-356. DOI:10.2174/1570160043377268

Publication Stats

2k Citations
173.81 Total Impact Points


  • 1997-2001
    • Kyushu University
      • • Department of Clinical Chemistry and Laboratory Medicine
      • • Graduate School of Medical Sciences
      • • Division of Internal Medicine
      Hukuoka, Fukuoka, Japan
  • 2000
    • Swansea University
      • Experimental Medicine Unit
      Swansea, Wales, United Kingdom
  • 1998
    • National Institute of Genetics
      • Division of Human Genetics
      Мисима, Shizuoka, Japan
  • 1993
    • Palo Alto Institute for Research and Education
      Palo Alto, California, United States
    • Molecular and Cellular Biology Program
      Seattle, Washington, United States